The RSPH4A Gene Primary Ciliary Dyskinesia Type 11 Genetic Test is a specialized diagnostic assessment offered by DNA Labs UAE, designed to identify mutations in the RSPH4A gene, which are implicated in Primary Ciliary Dyskinesia (PCD) Type 11. This condition is a rare genetic disorder that affects the cilia, tiny hair-like structures that line the airways, ears, and other parts of the body. PCD leads to chronic respiratory tract infections, sinusitis, and issues with fertility due to the impaired movement of cilia. Early and accurate diagnosis through genetic testing can be crucial for the management and treatment of the symptoms associated with this condition.
The test is priced at 4400 AED, reflecting the specialized nature of the genetic analysis and the advanced technology employed to achieve accurate results. Conducted at DNA Labs UAE, a facility known for its cutting-edge genetic testing services, this test provides essential information for individuals suspected of having PCD Type 11, enabling healthcare providers to tailor treatment strategies effectively. By pinpointing the specific genetic mutation, the test not only aids in the diagnosis but also helps in understanding the prognosis and potential familial implications of the condition.
The RSPH9 gene primary ciliary dyskinesia type 12 genetic test is a specialized diagnostic procedure designed to identify mutations in the RSPH9 gene, which are associated with primary ciliary dyskinesia (PCD) type 12. PCD is a rare genetic disorder that impairs the function of cilia, the microscopic, hair-like structures that line the airways, reproductive system, and other parts of the body. This impairment leads to various clinical manifestations, including chronic respiratory tract infections, reduced fertility, and situs inversus in some cases.
The test specifically targets the RSPH9 gene to confirm a diagnosis of PCD type 12, enabling healthcare providers to tailor treatment plans and management strategies to the individual needs of the patient. Early and accurate diagnosis through genetic testing can significantly improve the quality of life for affected individuals by allowing for timely interventions and support.
Administered by DNA Labs UAE, the test is available for a cost of 4400 AED. The facility utilizes advanced genetic sequencing technologies to ensure accurate and reliable results, providing essential information for individuals suspected of having this condition and their families. By opting for this test at DNA Labs UAE, patients can expect professional service and comprehensive support throughout the diagnostic process.
The DNAAF1 gene primary ciliary dyskinesia type 13 genetic test is a specialized diagnostic examination designed to identify mutations in the DNAAF1 gene, which are associated with primary ciliary dyskinesia (PCD) type 13. This condition is a rare genetic disorder characterized by abnormalities in the structure and function of cilia, leading to chronic respiratory tract infections, reduced fertility, and, in some cases, laterality defects. The test is crucial for accurate diagnosis, enabling targeted management and counseling for affected individuals and their families.
Performed at DNA Labs UAE, a leading facility in genetic testing, the test involves collecting a DNA sample, usually through a blood draw or cheek swab, and analyzing it for specific genetic alterations in the DNAAF1 gene. The cost of the test is 4400 AED, reflecting the specialized nature of the analysis and the advanced technology employed.
By providing a definitive diagnosis, the DNAAF1 gene primary ciliary dyskinesia type 13 genetic test plays a vital role in the care and treatment of patients with this condition, guiding therapeutic decisions and offering insight into the genetic basis of the disorder.
The LHFPL5 Gene Deafness Autosomal Recessive Type 67 Genetic Test is a specialized diagnostic procedure designed to identify mutations in the LHFPL5 gene, which are associated with autosomal recessive nonsyndromic hearing loss (DFNB67). This condition is characterized by the absence of hearing from birth or early childhood without other associated symptoms. The LHFPL5 gene plays a critical role in the development and function of the inner ear structures responsible for sound transmission.
This genetic test is crucial for families with a history of hearing loss, providing them with an accurate diagnosis and helping to guide potential treatment options or interventions. Early detection through this test can significantly impact the quality of life of affected individuals by facilitating timely access to hearing aids, cochlear implants, or other supportive measures.
Conducted at DNA Labs UAE, a leading facility in genetic testing, the test ensures precision, confidentiality, and reliability. The cost of the test is set at 4400 AED, reflecting the comprehensive analysis and expertise required to interpret the results accurately. DNA Labs UAE employs cutting-edge technology and follows strict international standards to ensure the highest quality of service.
By opting for the LHFPL5 Gene Deafness Autosomal Recessive Type 67 Genetic Test, individuals and families gain valuable insights into their genetic makeup, empowering them with the knowledge to make informed decisions about their health and well-being.
The TMC1 Gene Deafness Autosomal Recessive Type 7 Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, designed to identify mutations in the TMC1 gene that are known to cause Autosomal Recessive Non-Syndromic Hearing Loss (ARNSHL). This particular form of hearing loss, also referred to as DFNB7/11, is characterized by a deficiency in hearing that can range from moderate to profound, typically identified in early childhood. The TMC1 gene plays a crucial role in the development and function of the inner ear, and mutations in this gene disrupt the normal auditory process, leading to hearing impairment.
Given the genetic nature of this condition, the test is particularly valuable for individuals with a family history of hearing loss, aiming to understand their genetic status or assess the risk of passing the condition to their offspring. It's also a critical tool for early diagnosis in children showing signs of hearing impairment, allowing for timely intervention and management strategies to be implemented.
The test involves a simple blood draw or cheek swab, with the sample then analyzed in the state-of-the-art facilities at DNA Labs UAE. The cost of the test is set at 4400 AED, reflecting the comprehensive analysis and detailed reporting provided by the lab. Results from this test can offer crucial information for affected families, guiding decisions on management, treatment options, and genetic counseling.
The PNPT1 gene is associated with a form of deafness known as Autosomal Recessive Type 70 (DFNB70). This condition is characterized by a genetic mutation in the PNPT1 gene, which plays a crucial role in hearing. Individuals with mutations in both copies of their PNPT1 gene (one inherited from each parent) are at risk of developing this type of hearing loss. The condition underscores the importance of genetic factors in the auditory system's function.
To identify the presence of the specific genetic mutation associated with DFNB70, a genetic test is available at DNA Labs UAE. This test is crucial for families with a history of hearing loss or for individuals who have been diagnosed with an unidentified form of hearing impairment. By analyzing a sample of the patient's DNA, the test can detect mutations in the PNPT1 gene, thereby confirming or ruling out Autosomal Recessive Type 70 as the cause of deafness.
The cost of the PNPT1 Gene Deafness Autosomal Recessive Type 70 Genetic Test at DNA Labs UAE is 4400 AED. This price reflects the comprehensive analysis and the specialized technology required to accurately identify mutations in the PNPT1 gene. The test offers valuable information for affected individuals and their families, enabling informed decisions regarding management, treatment options, and genetic counseling.
The MSRB3 Gene Deafness Autosomal Recessive Type 74 Genetic Test is a specialized diagnostic tool designed to identify mutations in the MSRB3 gene, which are known to cause Autosomal Recessive Deafness 74 (DFNB74). This condition is characterized by non-syndromic sensorineural hearing loss, meaning it affects the inner ear or the neural connections to the brain responsible for hearing, without affecting other systems or parts of the body. The test is crucial for families with a history of hearing loss, as early detection can lead to more effective management and treatment options.
Performed at DNA Labs UAE, a leading facility in genetic diagnostics, the test involves collecting a DNA sample from the patient, usually through a blood draw or a cheek swab. The laboratory then analyzes the sample to detect any mutations in the MSRB3 gene that are associated with DFNB74. This process involves advanced genetic sequencing technologies to ensure accurate and reliable results.
The cost of the MSRB3 Gene Deafness Autosomal Recessive Type 74 Genetic Test is 4400 AED. While the price may seem high, it reflects the complexity of the genetic analysis and the invaluable information it provides to affected individuals and their families. This information can be crucial for making informed decisions about treatment options and for understanding the risk of passing the condition on to future generations.
The SYNE4 Gene Deafness Autosomal Recessive Type 76 Genetic Test is a specialized diagnostic tool designed to identify mutations in the SYNE4 gene, which are linked to Autosomal Recessive Deafness Type 76 (DFNB76). This condition is characterized by a form of non-syndromic sensorineural hearing loss, which means that the hearing impairment occurs without the presence of other signs or symptoms. Autosomal recessive inheritance means that an individual must inherit two copies of the mutated gene, one from each parent, to be affected by the condition.
The test involves analyzing the patient's DNA, extracted from a blood sample, to look for specific genetic alterations in the SYNE4 gene that are known to cause this type of hearing loss. This precise genetic testing can help in confirming a diagnosis, understanding the risk of passing the condition to offspring, and guiding treatment and management decisions.
The cost of the SYNE4 Gene Deafness Autosomal Recessive Type 76 Genetic Test is 4400 AED. This test is available at DNA Labs UAE, a facility equipped with advanced genetic testing technology and staffed by experts in the field of genetic diagnostics. DNA Labs UAE offers a range of genetic testing services, providing accurate and reliable results for patients and healthcare providers.
The LOXHD1 gene is responsible for encoding a protein that plays a crucial role in the normal functioning of the inner ear, particularly in the hair cells that are essential for hearing. Mutations in the LOXHD1 gene can lead to a form of hearing loss known as deafness, autosomal recessive type 77 (DFNB77). This condition is characterized by prelingual, non-syndromic sensorineural hearing loss, which means it occurs before speech development and is not associated with other symptoms. It is inherited in an autosomal recessive pattern, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to be affected.
To diagnose this specific type of genetic hearing loss, a genetic test targeting the LOXHD1 gene can be conducted. In the United Arab Emirates, DNA Labs UAE offers this specialized genetic test. The test involves analyzing the patient's DNA, extracted from a blood sample, to look for mutations in the LOXHD1 gene that are known to cause DFNB77. This test is crucial for early diagnosis and management of the condition, potentially allowing for interventions that could improve the quality of life for those affected.
The cost of the LOXHD1 gene deafness autosomal recessive type 77 genetic test at DNA Labs UAE is 4400 AED. This cost covers the process of collecting the sample, the genetic analysis, and the provision of a detailed report explaining the test results. For families with a history of this condition or for newborns showing signs of hearing loss, this test provides a valuable tool for confirming the diagnosis and guiding future care and treatment options.
The TPRN Gene Deafness Autosomal Recessive Type 79 Genetic Test is a specific diagnostic procedure aimed at identifying mutations in the TPRN gene, which are linked to a form of hereditary hearing loss. This condition, known as Autosomal Recessive Non-Syndromic Hearing Loss (ARNSHL) Type 79, is characterized by its genetic transmission mode, where an individual must inherit two copies of the mutated gene (one from each parent) to manifest the disorder. The TPRN gene plays a crucial role in the development and function of the inner ear, and mutations can lead to significant hearing impairment from birth or early childhood.
The test is available at DNA Labs UAE, a facility renowned for its advanced genetic testing capabilities and adherence to international standards of accuracy and confidentiality. The cost of the test is set at 4400 AED, reflecting the comprehensive analysis involved in detecting the specific genetic alterations associated with this form of deafness. By opting for this test, individuals with a family history of hearing loss can gain valuable insights into their genetic status, enabling informed decisions about family planning and access to early intervention services. Moreover, the results can guide healthcare professionals in tailoring personalized management and treatment plans for affected individuals, potentially improving their quality of life.
